Heron Therapeutics (HRTX) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Heron Therapeutics (HRTX) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 76.2% versus a loss of 84.5%. Over five years, MIST leads with a -93.8% price change compared with -97.3% for HRTX. Heron Therapeutics is the larger company by market cap ($48.0 million vs $46.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | MIST |
|---|---|---|
| Share price | $0.2525 | $0.3711 |
| Market cap | $48.04M | $46.20M |
| 1-day change | -4.39% | -7.06% |
| YTD return | -80.58% | -81.63% |
| 1-year return | -76.18% | -84.54% |
| 5-year return | -97.32% | -93.85% |
| EPS (TTM) | $-0.11 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $154.90M | — |
| Revenue growth (YoY) | +7.36% | — |
| Net income (latest FY) | $-20.20M | $-63.06M |
| Gross margin | 73.31% | — |
| Operating margin | -1.64% | — |
| Net margin | -13.04% | — |
| 52-week high | $1.58 | $3.06 |
| 52-week low | $0.2479 | $0.362 |
| Distance from 52-week high | -84.02% | -87.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +2672.28% | +1479.09% |
| Average volume | 4.56M | 1.53M |
| Shares outstanding | 190.27M | 124.50M |
| Employees | 128 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
HRTX vs MIST FAQ
Which is bigger, Heron Therapeutics or Milestone Pharmaceuticals?
Heron Therapeutics (HRTX) is larger, with a market capitalization of $48.04M compared with $46.20M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, HRTX or MIST?
HRTX returned -76.18% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and Milestone Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.